Cardiovascular disease is the leading cause of death among women, but the American Heart Association is working to change that. AtriCure is proud to support the AHA and their ongoing efforts in heart health research, education, and community programs, including the Heart Walk, CycleNation, Heart Ball, and the recent Go Red for Women Experience in Cincinnati. <a href="https://www.facebook.com/hashtag/
AHA" target="_blank">
#AHA</a> <a href="https://www.facebook.com/hashtag/AmericanHeartAssociation&quot; target="_blank">#AmericanHeartAssociation</a>

In the ICE-AFIB Trial, patients who received concomitant Cox-Maze III lesions using the cryoICE cryoFORM® Cryoablation probe during cardiac surgery experienced improvements in quality of life.*

In the ICE-AFIB Trial, patients who received concomitant Cox-Maze III lesions using the cryoICE cryoFORM® Cryoablation probe during cardiac surgery experienced improvements in quality of life.* ​

Mean QoL scores* improved by +32 points at 12 and 24 months compared to baseline – demonstrating durable benefit over time. ​

Read the full study: <a href="https://okt.to/qlLImZ&quot; target="_blank">https://okt.to/qlLImZ</a&gt; ​

*As calculated from the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. A 5-point change is considered clinically meaningful. ​

Another quarter, another step forward. Our Q1 results highlight the impact of our strategy in action.

Read the full earnings report: <a href="https://t.co/NIzAWdN4fk&quot; target="_blank">https://t.co/NIzAWdN4fk</a&gt;
 
<a href="https://twitter.com/hashtag/Earnings?src=hashtag_click&quot; target="_blank">#Earnings</a> <a href="https://twitter.com/hashtag/FinancialResults?src=hashtag_click&quot; target="_blank">#FinancialResults</a>

Another quarter, another step forward. Our Q1 results highlight the impact of our strategy in action.

Read the full earnings report: <a href="https://okt.to/I3rK5q&quot; target="_blank">https://okt.to/I3rK5q</a&gt;

<a href='https://www.linkedin.com/feed/hashtag/?keywords=Earnings&highlightedUpd…; target='_blank'>#Earnings</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=FinancialResults&highli…; target='_blank'>#FinancialResults</a>

<a href="https://twitter.com/hashtag/AATS2026?src=hashtag_click&quot; target="_blank">#AATS2026</a> was one for the books. Through our CME symposium and exhibit floor conversations, we connected with surgeons to discuss the AtriClip portfolio for LAAE, its use with the EnCompass clamp in a single &amp; the cryoSPHERE® MAX probe for post-op pain management. Thanks for

<a href='https://www.linkedin.com/feed/hashtag/?keywords=AATS2026&highlightedUpd…; target='_blank'>#AATS2026</a> was one for the books. Through our CME symposium and conversations on the exhibit floor, we connected with surgeons to explore the AtriClip portfolio for LAA exclusion, its use alongside the Isolator® Synergy™ EnCompass® clamp in a single procedure, and the role of the cryoSPHERE® MAX probe in post-operative pain management. Thanks to everyone who stopped by!

In exclusion, confidence comes from completeness.

AtriClip’s straight profile is engineered for full tissue capture and uniform compression—delivering complete, reliable closure and the durable exclusion clinicians expect and patients deserve. 

Learn more:

In exclusion, confidence comes from completeness.

AtriClip’s straight profile is intentionally designed to deliver full tissue capture and uniform compression, helping ensure complete, reliable closure. The result is the confident, durable exclusion clinicians expect and patients deserve.

Discover the intentional design behind AtriClip’s reliable LAA exclusion: <a href="https://okt.to/jFKQJg&quot; target="_blank">https://okt.to/jFKQJg</a&gt;

<a href='https://www.linkedin.com/feed/hashtag/?keywords=LAAExclusion&highlighte…; target='_blank'>#LAAExclusion</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=AtriClip&highlightedUpd…; target='_blank'>#AtriClip</a>

Did you know the ABLATE Post-Approval Study required all surgeons to complete AtriCure’s training course?

70 surgeons across 40 sites treated 363 patients with the Cox-Maze IV using AtriCure’s Synergy RF Technology.

The outcomes speak for themselves:

Freedom from Afib at 3 years: 76% on/off AADs, 64% off AADs

0 device‑related complications

With AtriCure’s proven Synergy technology, durable, life-changing Afib results are possible for any trained surgeon — not just the highly experienced.

Learn more about ABLATE PAS and its real-world impact: <a href="https://okt.to/mJyfFe&quot; target="_blank">https://okt.to/mJyfFe</a&gt;